Physician Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Agennix Incorporated
Oral talactoferrin improved response rates in lung cancer
June 15th, 2005
Agennix Incorporated announced results from a double-blind, randomized, placebo-controlled, multicenter phase II clinical trial evaluating oral talactoferrin alfa (talactoferrin). Talactoferrin was combined with standard chemotherapy and compared to placebo plus standard chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC). Data on the primary endpoint (best overall response by CT scan using RECIST criteria) was presented at the American Association for Cancer Research (AACR) annual meeting. The trial met its primary endpoint of detecting an improvement in response rate (p=0.05). Results from tumor related secondary...
Source: Physician Law Weekly (2005-06-15)
|
